Colorectal cancer

Indexed in Crossref

180 abstracts matching colorectal cancer from the meeting's journal supplement, fetched live from Crossref 2026-11-12 10:31 UTC. This is a keyword search, not the complete abstract book.

• E15554
  Tislelizumab combined with bevacizumab and trifluridine/tipiracil as third-line or later therapy for metastatic colorectal cancer (mCRC) : A real-world study.

  Luping Lin, Sha Huang, Jianwei Yang
• E15604
  Current real-world treatments in patients with metastatic colorectal cancer (mCRC) in US clinical practice.

  Xiaoyun Pan, Orsolya Lunacsek, Jamie Grossman, Svetlana Babajanyan et al.
• E23082
  Variation in metastatic colorectal cancer (mCRC) patient survival among different oncology practice settings with guideline-concordant molecular testing.

  Tony Varughese, Wenners Ballard, Chiranjeev Dash, Connor Shimberg et al.
• E23288
  The COMPLETE-CRC screening initiative: Increasing colonoscopy completion after positive stool-based colorectal cancer screening.

  Akram Abushamma, Carole Macaron, Susannah Wolfe, Gabriella Lakatos et al.
• 3534
  A randomized phase II trial of fruquintinib plus capecitabine versus capecitabine alone as maintenance therapy following first-line chemotherapy in metastatic colorectal cancer (mCRC).

  Wenhua Li, Jinjia Chang, Zhiyu Chen, Junjie Peng
• E15535
  Impact of KRAS sub-mutations in metastatic colorectal cancer patients (mCRC).

  Elena Astore, Samantha Mignogna, Lella Petrella, Maria De Ninno et al.
• E15584
  Traditional Chinese medicine (TCM) for prevention and management of anti-EGFR monoclonal antibody (mAb)–induced cutaneous adverse reactions in patients with metastatic colorectal cancer (mCRC): A retrospective analysis.

  JiaNi Shi, HaiTao Jiang, Jian Yuan, Yangxian Xu
• 3659
  Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations, and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD).

  Alicia Catania McDonald, Joy Saha, David R. Fogelman, Carol Elaine Pena et al.
• TPS10632
  SOLAR: A post-approval study evaluating longitudinal performance of a blood-based test for screening individuals at average risk for colorectal cancer (CRC).

  Sam Asgarian, Sylvia Hu, Hannah Oakley, Craig Eagle
• E15560
  Intermittent fruquintinib plus trifluridine/tipiracil in refractory metastatic colorectal cancer (mCRC): A single-center, single-arm phase II study.

  Jiayu Niu, Huiqin Luo, Wenju Chen, Mengge Li et al.
• E15589
  Attenuation of long-term survival benefit of biological therapy in metastatic colorectal cancer (mCRC): Real-world data validation and molecular characterization.

  Sanjay Goel, Yasmine Baca, Joanne Xiu, Heinz-Josef Lenz et al.
• TPS3177
  Beamion BCGC-1: Four new phase Ib/II cohorts to evaluate oral zongertinib with other agents in HER2-positive metastatic breast cancer (mBC) and metastatic colorectal cancer (mCRC).

  Kohei Shitara, Izuma Nakayama, Shigehisa Kitano, Ramon Yarza et al.
• 3528
  Fruquintinib plus FOLFIRI or mFOLFOX6 as second-line therapy for patients with RAS -mutant metastatic colorectal cancer (mCRC): A phase II, multicenter, open-label study.

  Yun Xu, Ye Xu, Ming Tang, Cong Li et al.
• 3608
  Liver transplantation (LT) in liver limited metastatic colorectal cancer (CRC): Insights and opportunities.

  Jonathan W. Lee, Juan P. Rocca, Benjamin Samstein, Anthony J. Choi et al.
• E15622
  Safety and efficacy of ST316, a first in class ß-catenin antagonist, in metastatic colorectal cancer (mCRC).

  Anthony B. El-Khoueiry, Susanna Varkey Ulahannan, E. Gabriela Chiorean, Steven Francis Powell et al.
• 3579
  Indirect comparison of nivolumab-ipilimumab versus chemotherapy (Chemo) and/or immunotherapy in dMMR/MSI-H metastatic colorectal cancer (mCRC) using reconstructed individual patient data (IPD).

  Daniele Rossini, Federico Nichetti, Camilla Motola, Maria Caterina De Grandis et al.
• 3576
  Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study.

  David Berz, Yanhong Deng, Jianwei Zhang, Zhiwei Li et al.
• 3600
  An early on-treatment "coordinated inflammatory niche" plasma signature as a predictor of response in the SYLT026 trial: Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite-stable/proficient mismatch repair (MSS/pMMR) metastatic colorectal cancer (mCRC).

  Yi Yin, Jun Xiao, Liyu Su, Rongbo Lin
• E15657
  The impact of aspirin use on pathological outcomes in locally advanced rectal cancer patients undergoing total neoadjuvant therapy: Real-world data from the Ankara University Colorectal Cancer study group.

  Satı Coskun Yazgan, Cihangir Akhyol, Ayhan Kuzu, Mehmet Ali Koç et al.
• E15539
  Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.

  Wangjun Liao, Min Shi, Xiaoxiang Rong, Siting Zheng et al.
• TPS3682
  A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3.

  Aparna Raj Parikh, Michael J. Overman, Christopher T. Chen, Elena Elez et al.
• E15608
  What is left in pMMR/MSS BRAF V600E metastatic colorectal cancer (mCRC)? Prognostic role of tumor sidedness and molecular co-mutations.

  Eleonora Perissinotto, Rossana Intini, Giulia Maddalena, Riccardo Cerantola et al.
• 3606
  Dynamics of circulating monomeric C-reactive protein (mCRP) to predict outcomes with first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

  Anniken Joerlo Fuglestad, Paula A. Bousquet, Lawrence A. Potempa, Marc Potempa et al.
• 3553
  Detecting MTAP loss in liquid biopsies from patients with clinically advanced colorectal cancer (CRC).

  Xuanyi Li, Miriam Saffern, Dean C. Pavlick, Alexa Betzig Schrock et al.
• E15621
  Artificial intelligence–guided microsatellite instability classification in colorectal cancer (CRC): EfficientNet-based histopathology analysis for precision treatment planning.

  Hammad Khan, Elangovan Krishnan, Shankar Biswas, Jansi Rani Sethuraj et al.
• E15525
  Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.

  Pashtoon Murtaza Kasi, Ari David Baron, Arvind Chaudhry, Laura LaNiel Tenner et al.
• 3529
  daNIS-3: A phase II platform study of NIS793 and anti–PD-1 combined with standard of care (SoC) anti-cancer therapy for the second-line (2L) treatment (tx) of microsatellite-stable colorectal cancer (MSS CRC).

  Filippo Pietrantonio, Iosune Baraibar, Jiri Tomasek, Neil Howard Segal et al.
• 3574
  Contribution of atezolizumab (atezo) to the efficacy of the zanzalintinib (zanza) + atezo combination in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Evidence from the phase 3 STELLAR-303 trial.

  Anees Dauki, Mun Sang Yue, Reza Khosravan, Cixin He et al.
• 3510
  Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC): Interim results from the phase 2 randomized CRDF-004 trial.

  Heinz-Josef Lenz, Hao Xie, Daniel H. Ahn, David L. Bajor et al.
• 3616
  Minimal residual disease (MRD) assessment by circulating tumor DNA (ctDNA) to stratify recurrence risk and adjuvant treatment benefit in a real-world colorectal cancer (CRC) cohort.

  Mariem Galuia, Joseph Gabriel Mchayleh, Lampros Karakozis, Michael Abdelmasseh et al.
• 3648
  Rates of metachronous colorectal cancer or secondary Lynch syndrome–related cancers in patients with non-metastatic colorectal cancer.

  Emily M. Russell, Sarah Nielsen Young, Erica M. Vaccari, Heidi C. Ko et al.
• E15596
  Comprehensive genomic landscape of early-onset colorectal cancer: A comparative analysis with average-onset metastatic colorectal cancer in a next-generation sequencing cohort of 1,892 patients.

  Ji Eun Shin, Minsuk Kwon, Sung Hee Lim, Jeeyun Lee et al.
• E15626
  Molecularly defined subgroups within RAS-WT mCRC: Treatment selection and overall survival in Project GENIE BPC CRC Database.

  Aayushi Pareek, Kartik Dapke, Manaswini Krishnakumar, Sai Dinesh Yerramalla et al.
• E15619
  Impact of concurrent tissue (TBx) and liquid (LBx)–based comprehensive genomic profiling (CGP) on biomarker detection and first-line (1L) treatment in metastatic CRC (mCRC).

  Jessica Lee, Amaya Gasco Hernandez, Richard Sheng Poe Huang, Marwan Fakih
• 3504
  SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAF V600E metastatic colorectal cancer (mCRC).

  Van K. Morris, Sarah Colby, Scott Kopetz, Katherine A. Guthrie et al.
• 3505
  Phase 3 trial of trastuzumab rezetecan vs standard of care (SOC) for chemotherapy-refractory, HER2-positive, advanced colorectal cancer (CRC).

  Jin Li, Ying Yuan, Tianshu Liu, Xiuying Xiao et al.
• E15645
  Early-onset colorectal cancer: 2-year analyses of Georgian cancer registry.

  Tamar Esakia, Marina Maglakelidze, Davit Kvaratskhelia, Nino Sharikadze et al.
• E15550
  Real-world treatment patterns and clinical outcomes for patients with deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC).

  Vanessa Wong, Grace Kim, Matthew Loft, Belinda Lee et al.
• 3581
  Propensity score–matched analysis of trifluridine-tipiracil plus bevacizumab (FTD/TPI+Bev) vs anti-EGFR re-treatment in pretreated metastatic colorectal cancer (mCRC).

  Giovanni Trovato, Daniele Rossini, Paolo Ciracì, Chiara Cavalli et al.
• LBA3503
  BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

  Scott Kopetz, Josep Tabernero, Sara Lonardi, Lin Shen et al.
• E15576
  Clinicopathologic profile and comparative performance of limited next-generation sequencing and qPCR for detection of RAS/RAF mutations in stage IV colorectal cancer (mCRC).

  Soumya Surath Panda, Ayush Dubey, Subhashree Subhasmita Dash, Debahuti Mohapatra et al.
• 3560
  FOLFOXIRI/bevacizumab in microsatellite stable (pMMR/MSS) RAS and BRAF wild-type “gene-altered” metastatic colorectal cancer (mCRC): The HYPERTRIBE study.

  Marco Maria Germani, Rossella Bruno, Mariam Polito, Roberta Fazio et al.
• 3511
  Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib + panitumumab efficacy and prognosis in KRAS G12C–mutated colorectal cancer (mCRC): Results from phase 3 CodeBreaK 300.

  Filippo Pietrantonio, Lata Mukundan, Abraham Anderson, Emily Chan et al.
• TPS3681
  Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).

  Javier Ros Montañá, Susana Roselló, David Paez, Maria Jose Safont et al.
• 3561
  Tumor load change as a functional biomarker for prognosis and treatment modulation in metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of 12 randomized trials.

  Alexej Ballhausen, Marco Maria Germani, Volker Heinemann, Daniele Rossini et al.
• 3539
  First-line immune checkpoint inhibitors in elderly colorectal cancer patients in the real world: Retrospective phase of the multicenter ELDER CRC trial.

  Martina Cassaniti, Alessandra Boccaccino, Daniele Rossini, Lisa Salvatore et al.
• E15541
  Clinical characterization and survival of patients (pts) with PIK3CA -mutated metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of four randomized trials.

  Arndt Stahler, Julia Anna Theresia Stahler, Dominik Paul Modest, Ludwig Fischer Von Weikersthal et al.
• TPS3672
  Phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy versus bevacizumab plus chemotherapy in previously untreated, unresectable, or metastatic colorectal cancer (ROSETTA CRC-203).

  Tiago Biachi de Castria, Ian Chau, Elena Elez, Akihito Kawazoe et al.
• 3665
  Bowel function after sphincter-preserving treatment with neoadjuvant therapy for low rectal cancer.

  Yuanshan Chen, Qiyuan Qin, Yikan Cheng
• TPS3675
  Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).

  Cathy Eng, Elena Elez, Julien Taieb, Rui-Hua Xu et al.
• 3607
  The SERPENTINE trial: A phase II clinical study decoding immune responses by scRNA-seq and TCR-seq analysis in patients with MSS metastatic colorectal cancer (mCRC) with and without liver metastases treated with durvalumab and tremelimumab.

  Iosune Baraibar, Sam Morabito, Juan Nieto, Gerard Deuner et al.
• TPS3683
  INCA033890-303: A randomized, double-blind, phase 3 study of FOLFOX and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite-stable colorectal cancer.

  Van K. Morris, Miguel Colon Donate, Jenny Seligmann, Atsuo Takashima et al.
• 3513
  Development of a computational histology artificial intelligence (CHAI)–powered predictive biomarker for first-line chemotherapy intensification in metastatic colorectal cancer (mCRC) and validation in prospective randomized phase III trials (RCT).

  Paolo Ciracì, Viswesh Krishna, Carlotta Antoniotti, Giulia Martinelli et al.
• 3547
  Serum VEGF-A concentrations as a predictive biomarker of immunotherapy response in refractory metastatic colorectal cancer (mCRC): An exploratory analysis of CCTG CO.26.

  François Jobin Gervais, Xin Wang, Jonathan M. Loree, Emma Titmuss et al.
• 2647
  Mitochondrial DNA (mtDNA) expression as used to define metabolic and immune states in colorectal cancer (CRC).

  Michela Bartolini, Sharon Wu, Joanne Xiu, Ninad Kulkarni et al.
• E15727
  Sulfidogenic bacteria and the risk of colorectal cancer.

  Darren Lee, Nicholas Ollberding, Qing Duan, Jordan Kharofa
• E15739
  Spatial immune architecture as a predictor of response to neoadjuvant chemoradiotherapy in rectal cancer.

  Rachel Violet Purcell, Adèle Hegoburu, Arielle Sulit, Frank Frizelle
• 3637
  Comparison of longitudinal circulating tumor DNA (ctDNA) and carcinoembryonic antigen (CEA) for post-operative risk stratification in colorectal cancer (CRC).

  Eiji Oki, Koji Ando, Hideaki Bando, Yoshiaki Nakamura et al.
• E15698
  Associations between chronic pain, depression, and social vulnerability in US adults with colon cancer.

  Aimee Pehrson, Omar Ramos, Andrew Russ
• 10579
  Structural disparities in early-onset colorectal cancer mortality: A national county-level analysis.

  Varshini Odayar
• E15716
  The obesity paradox in colon cancer hospitalizations: Mortality and cardiovascular risk.

  Katya Christina Andrade Benavides, Daniel Cruceta Reynoso, Cesar O. Ortiz
• 3538
  Zongertinib in HER2-altered colorectal cancer: A pooled analysis of colorectal cancer patients from two clinical trials.

  Dirk Arnold, Noboru Yamamoto, Frans Opdam, Kiyotaka Yoh et al.
• E15640
  A novel regimen of liposomal irinotecan plus capecitabine as total neoadjuvant therapy for locally advanced rectal cancer (LipCap): A phase II trial.

  Linlin Xiao, Fengpeng Wu
• E15643
  Multiomic profiling of early onset colorectal cancer in an irish tertiary cancer centre: Outcomes and correlative insights.

  Mary O. Reilly, Kieran Sheahan, Kieran Wynne, Des C. Winter et al.
• E15710
  Clinical outcome of Asian and non-Hispanic White patients with colorectal cancer in a NCI-designated cancer center serving a diverse catchment area.

  Abhiraj Saxena, Christina Boatwright, Hrithik Kumar, Aakash Shetty et al.
• E24021
  Mortality trends involving colon cancer and atrial fibrillation in the United States,1999-2023: A CDC WONDER analysis.

  Hajira Mahboob, Shiva Kumar
• 3516
  Real-world outcomes and circulating tumor DNA (ctDNA) dynamics in patients (pts) with microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI).

  Hannah Ruth Robinson, Nicholas James Hornstein, Patrick M. Boland, Daniel H. Ahn et al.
• 3628
  Impact of postsurgical circulating tumor DNA (ctDNA) dynamics on eligibility of colorectal cancer (CRC) patients for randomized ALTAIR trial: Implications for treat-on-molecular-recurrence (TOMR) trials.

  Hideaki Bando, Yoshiaki Nakamura, Vasily N. Aushev, Jun Watanabe et al.
• 3501
  Informing optimal duration of adjuvant chemotherapy (ACT) in resected stage I-IV colorectal cancer (CRC) based on early circulating tumor DNA (ctDNA) dynamics.

  Hiroyuki Yamamoto, Hideaki Bando, Yoshiaki Nakamura, Daisuke Kotani et al.
• E13778
  Relative benefit of perioperative chemotherapy after resection for stage III colon cancer in the 70s age range: SEER 2004–2015.

  Leeseul Kim
• 3532
  Nivolumab + ipilimumab (NIVO + IPI) vs NIVO in microsatellite instability high/mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC): CheckMate 8HW subgroup analyses including treatment-free status and outcomes in long-term survivors.

  Elena Elez, Thierry Andre, Sara Lonardi, Heinz-Josef Lenz et al.
• 2575
  Plasma-TMB (pTMB) and circulating tumor fraction (ctF) dynamics as biomarkers of benefit from the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer (mCRC): A translational analysis of the AtezoTRIBE study.

  Veronica Conca, Michelle Ting-Lin, Roberto Moretto, Xifeng Wang et al.
• E15575
  Effects of RNA-based NGS on false-positive fusion calls in colorectal cancer compared with DNA-NGS.

  Qizhi Liu
• 3611
  Dual-microbial signature as a predictor of postoperative colorectal cancer recurrence.

  Pancheng Chen, Yanlei Ma, Jinming Li
• E15736
  A distinct immune–microbiome axis in early-onset colorectal cancer.

  Rachel Violet Purcell, Oliver Waddell, Arielle Sulit, Frank Frizelle
• 3655
  Organ preservation and local excision for rectal cancer: Long-term oncologic outcomes.

  Avihai Moscovici, Tyler Bogaczyk, Hien Anh Ton, Erik L. Zeger et al.
• E15523
  Integrating metabolic response and circulating tumor biomarkers as early indicators of therapy outcome in locally advanced inoperable rectal cancer.

  Suresh VS Attili, Rakesh Sharma, Vidya Sagar Dusi
• E14524
  Immune microenvironment, MSI status, and tumor mutational burden as prognostic factors in colorectal cancer.

  Shivani Modi, Sneha Singh, Himil Mahadevia
• 3623
  Stage-specific circulating tumor DNA (ctDNA) positivity and minimal residual disease (MRD) decision making in colorectal cancer (CRC) in the prospective INTERCEPT program.

  Emerik Osterlund, Giulia Maddalena, Guglielmo Vetere, Kathryn Aziz et al.
• E15639
  Colorectal cancer risk in cystic fibrosis: Systemic review and quantitative synthesis of epidemiologic, genetic, and clinical evidence.

  Sameera Sunkara, Chandana Dasari
• 11176
  Assessing burden and outcomes: Colon cancer survival across the U.S. safety-net spectrum.

  David Otohinoyi, Sravya Sri Kuchipudi, Amit Rajkarnikar, Farha Khan et al.
• E15692
  Trends in early-onset colorectal cancer incidence (2000–2022) among Black Americans and Sub-Saharan African populations.

  Ahmed Minhas, Owais Syed
• 3543
  Survival outcomes of human epidermal growth factor receptor 2 (HER2)–amplified and HER2-mutated left-sided colorectal cancer (CRC) patients treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).

  Yu Jen Alexander Jan, Kieran Sweeney, Andrew Elliott, Ronan Wenhan Hsieh et al.
• E15542
  Targetable genomic alterations in early-onset colorectal cancer and their therapeutic implications: Real-world data.

  Yostena Nagy Mekhail, Konstantinos Vellios Kamposioras
• E15634
  Association of neoadjuvant therapy with perineural invasion and postoperative survival in locally advanced colon cancer.

  Mohyeddine El Sayed, Virgilio George, Maggie Westfal, Thomas Curran et al.
• E13756
  Length of stay, costs, and mortality in colon cancer: A regional comparison between the northeast and west.

  Shruthi Sridhar, Daniel Cruceta Reynoso, Cesar O. Ortiz
• E15648
  Pathologic response in relation to total neoadjuvant therapy sequence, completion, and extra consolidation chemotherapy in locally advanced rectal cancer.

  Mehmetcan Atak, Gizem Kavak, Yildiz Guney, Aysegul Ilhan et al.
• E15676
  Incidence of early-onset colorectal cancer in the United States: A population-based analysis (2000-2019).

  Tahreem Malik, Thomas Greco, Joseph Maslak
• E15658
  Exploration of tumor-informed ctDNA detection and dynamics in a real-world cohort of colorectal cancer patients from the MD Anderson Cancer Center.

  Christopher Gareth Smith, Kathryn Aziz, Lisa Gates, Melanie Hussong et al.
• 3521
  Large language model–assisted decision-making in multidisciplinary tumor boards for colorectal cancer.

  Aydan Farzaliyeva, Arzu Oguz, Ozden Altundag, Zafer Akcali
• 10525
  Cost-effective colorectal cancer screening in the United States: Comparative analyses of four molecular tests.

  Yinyin Chang, Shujia Hao, Mao Mao
• E15630
  Operative and non-operative management of small bowel obstruction in colorectal cancer hospitalizations: A national inpatient sample analysis.

  Ayesha Kang, Muhammad Haris Latif
• E23378
  Reporting of propranolol use in studies of beta-blockers in colorectal cancer.

  Norman R. Williams, Monica Georgette Bassous, Elizabeth A. Davies, Aamir Ahmed
• E15096
  Clinical candidate JNC-1043, importin ß inhibitor (first in class), to target incurable cancers, TNBC, and colon cancer.

  Jong-Ryoo Choi, Jong-Kuk Park, Sung-Kyun Ko
• E15618
  Updated analysis of adjuvant chemotherapy after radical resection of metachronous colorectal cancer metastases.

  Sevindzh Evdokimova, Anna Kornietskaya, Larisa Bolotina, Mikhail Fedyanin et al.
• E22536
  Adherence to lower endoscopic surveillance in high-risk colorectal cancer populations: A meta-analysis of U.S. studies.

  Anne Lincoln, Jaydeep Mahasamudram, Luigi Ricciardiello
• E15719
  Germline pathogenic variants in early-onset colorectal cancer and limitations of tumor-based screening.

  Jessica Shostak, Abigail Huetteman, Aaron Bertolo, Satish Stephen Maharaj
• E14552
  Turning clinically approved PARP inhibitors into immunotherapy sensitizers by reprogramming the tumor microenvironment in colorectal cancer.

  Mai M. Abouzeid, Mohamed Ghonim, Hamid Boulares
• 3524
  Validation of DiaSurv, an AI-based algorithm for stage II colon cancer risk stratification.

  Lou Rouan, Céline Bossard, Baptiste Gourdin, Yahia Salhi et al.
• LBA3508
  Adjuvant aspirin for stage III colorectal cancer after curative resection: Primary analysis of the randomized double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C).

  Atsuo Takashima, Yasumitsu Hirano, Manabu Shiozawa, Hideki Ueno et al.
• 3550
  Negative hyperselection as a predictive biomarker of benefit from first-line doublets + anti-EGFRs/bevacizumab (bev) in microsatellite stable (pMMR/MSS) RAS and BRAF wild-type (wt) and HER2− metastatic colorectal cancer (mCRC): An individual patient data pooled analysis of seven clinical trials (CTs).

  Marco Maria Germani, Roberto Moretto, Tadayoshi Hashimoto, Volker Heinemann et al.
• E15650
  Induction CAPOX as part of total neoadjuvant therapy for high-risk locally advanced rectal cancer: Long-term real-world outcomes from two centers.

  Stephanie Prince, Maxine Flubacher, Ben Masters, Andrew Rea Bateman
• E15566
  Efficacy and safety of bevacizumab biosimilars in metastatic colorectal cancer: A pairwise and network meta-analysis.

  Paulami Deshmukh, Yogita Karandikar, Uma Bhosale, Chetan Deshmukh
• E22650
  Prevalence of the TCF7L2 rs7903146 T allele in young Hispanic adults: Implications for colorectal cancer prevention.

  Brenden Reyes, Naina Sharma, Laura Mier, Dahis Manzanares
• E15738
  Characterizing patient outcomes and tumor genetics in perinatal early-onset colorectal cancer patients.

  Matthew Robert Moldenhauer, Irene Su, Nicole Elizabeth Lopez, Gregory P. Botta
• E15577
  Uncoupling of MT1E transcription and translation in high-CNA colorectal cancer: A proteostatic adaptation as driver of aggressiveness.

  Wen-Ying Lin, Hao-Wei Teng
• 10004
  The ASPIRES study: Promoting colorectal cancer surveillance in childhood cancer survivors—A randomized intervention trial from the Childhood Cancer Survivor study (CCSS).

  Tara O. Henderson, Jenna Bardwell, Chaya S. Moskowitz, Lindsay F. Schwartz et al.
• 3636
  Relationship between GLP-1 receptor agonists on cancer recurrence and survival of patients with stage I-III colorectal cancer: A retrospective cohort study using the TriNetX database.

  Emily Noelle Kinsey, Kristina Lee Tatum, Carolina Velez-Mejia, Alisha Sharma et al.
• E15704
  Early-onset colorectal cancer in a developing region: A five-year real-world analysis from Brazil.

  Sabina B. Aleixo, Jose Zago Pulido, Alice Aleixo Pulido
• E15660
  National mortality trends in colorectal cancer patients with psychiatric and respiratory comorbidities in the United States,1999-2023: A CDC WONDER analysis.

  Hajira Mahboob, Shiva Kumar
• E23067
  Failure to rescue following colorectal cancer surgery at minority-serving hospitals: A National Inpatient Sample analysis.

  Austin Qasawa, Eli Tidwell, Rishita Gupta, Charles Tobin et al.
• E13747
  Association between physical disability status and up-to-date colorectal cancer screening: A cross-sectional study.

  Kallyn Bravo, Teana Tee, Cara Gillespie, Noel Christopher Barengo
• E15661
  Sensitivity detection of colorectal precancerous lesions and cancer by assessing cell-free multimodal chromatin states in plasma.

  Xubin Chen, Xiaoxuan Meng, Weilong Zhang, Aibin He
• E15679
  Medicaid expansion and timely colorectal cancer treatment initiation among young adults in Virginia.

  Paulette Omeaku, Arnethea Sutton, Bassam Dahman, Erin Britton et al.
• TPS3678
  A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability–low (MSI-L) colorectal cancer (CRC).

  Alexander I. Spira, David Sommerhalder, Annie Winterhall, Tonia Jane Buchholz et al.
• E15709
  State-level trends in colorectal cancer incidence and stage before and during the COVID-19 pandemic.

  Bakr Alhayek, Malaka Abubakir, Susmita Potti, Omar M. Abdel-Rahman Abdelsalam
• E15623
  Efficacy and safety of third-line treatments in metastatic colorectal cancer: A meta-analysis.

  Abdullah Esmail, Waseem Abdelrahim, Yazan Hamadneh, Nour Maher Mustafa et al.
• E22580
  Exploring the genotoxic and tumorigenic potential of artificial food dyes and implications for colorectal cancer risk in socioeconomically disadvantaged communities.

  Rajan Bell, Andres Simon, Julie R. Gralow
• E15157
  Impact of engineered probiotic expressing FomA-targeted antimicrobial peptides on intestinal tumorigenesis in a mouse model of Fusobacterium nucleatum –associated colorectal cancer.

  Kristen Leigh Greathouse
• 12085
  Cognitive impairment during anti-EGFR targeted therapy in metastatic colorectal cancer patients.

  Liubov Yu Vladimirova, Elvina Gevorkyan, Alexey Bobrov, Natalia Semenova et al.
• E14598
  Distinct biological and immune microenvironment features of MSI-H BRAF V600E colorectal cancer: Potential for combined PD-1, BRAF, and EGFR inhibition.

  Lulu He, Feng Guo
• E15700
  Colon cancer sidedness in relation to sepsis risk and clinical predictors: A National Inpatient Sample analysis.

  Panah Tushar Parab, Edwin Saji, Jason Jacob, Akshat Saxena et al.
• E15686
  Trends in locoregional colorectal cancer incidence by socioeconomic factors in US adults aged 45-49 with updated screening guidelines (2013-2022).

  Jerry Kong, Matthew Tucker, Peter Liang
• E15571
  Phase I study of liposomal irinotecan plus fruquintinib as third- or later-line therapy for metastatic colorectal cancer.

  Qian Li, Yongqiang Li, Zongjia Wang, Meifang Pan et al.
• E15627
  Real-world use of regorafenib for refractory metastatic colorectal cancer: Survival outcomes and associated clinical features.

  Bo-Wen Lin, Chun-Hsien Wu, Ren-Hao Chan, Yu-Min Yeh
• E15620
  Safety and efficacy of chemotherapy in metastatic colorectal cancer with liver dysfunction due to hepatic metastases: A systematic review.

  Adrian Bailey, Robert Hovey, Ru Min, Derek J. Jonker
• E23306
  Impact of a resident-led quality improvement intervention on colorectal cancer screening completion at a federally qualified health center.

  Sujata Ojha, Taylor Landry, Boone Goodgame, Veena Patel
• E15725
  Anatomical and clinical heterogeneity of dMMR colorectal cancer by tumor location.

  Fei Li, Ping Yang, Tao Jiang, Fenge Jiang et al.
• E15697
  Clinical outcomes for low-income patients with early-onset colorectal cancer: An analysis of the National Inpatient Sample.

  Vineet Polineni, Tony Elias, Danielle Claire Thor, Ben Brik
• E15540
  Tislelizumab, bevacizumab, and chemotherapy as second-line therapy in PD-L1-positive, RAS-mutant metastatic colorectal cancer: A single-arm, phase II clinical trial.

  Luoyan Ai, Xiaojing Xu
• E15687
  Racial and ethnic differences in colorectal cancer screening effectiveness in the PLCO trial.

  Yoshito Nishimura, Ayane Okuda, Kotomi Yamanaka, Mana Murakami et al.
• E15558
  Immune-related thyroid dysfunction and overall survival in metastatic colorectal cancer treated with pembrolizumab: A real-world TriNetX analysis.

  Baqir Jafry, Farzeen Fatma Syed, Jennifer Collins, Amir Kamran
• E15549
  Surgical efficacy and complications of cytoreductive surgery with HIPEC for colorectal cancer patients with peritoneal carcinomatosis.

  Meng-Kai Hsu, Tzu-Chun Chen, Jin-Tung Liang, Hsin-Yang Lee
• 3523
  HistoChrome: Virtual multiplex immunohistochemistry from routine H&E in colorectal cancer.

  Mark Eastwood, Zedong Hu, Gertjan Rasschaert, Petros Tsantoulis et al.
• 3599
  Prediction of hematotoxicity using CT-derived body composition in rectal cancer patients receiving immunotherapy-based total neoadjuvant therapy.

  Ruone Xu, Wang Yang, Xiaoming Sun, Luoxi He et al.
• E15649
  Predicting pathological complete response based on multi-time point 18 F-FAPI PET/CT in locally advanced rectal cancer.

  Minyi He, Huiting Yang, Yunxing Shi, Rongqin Zhang et al.
• E15552
  Prognostic and predictive value of baseline derived neutrophil-to-lymphocyte ratio (dNLR) in RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving 5-fluorouracil and folinic acid (FU/FA) with or without panitumumab (Pmab) maintenance: A post-hoc analysis of the PANAMA/AIO KRK 0212) trial.

  Tobias Schaetzl, Dominik Paul Modest, Sebastian Stintzing, Lothar Müller et al.
• E15654
  A prospective, single-arm, single-center observational clinical study on envafolimab (PD-L1 inhibitor) in combination with XELOX for neoadjuvant treatment of locally advanced colon cancer.

  Hui Li, Cheng - Wei, Sheng - Liu, Luchuan Chen
• E15711
  Pre-existing mental health diagnosis and colorectal cancer outcomes.

  Hasiya Yusuf, Elham Babadi, Tarrant McPherson, Ruoyu Miao et al.
• TPS3679
  A study evaluating microbiome modulation therapy in patients undergoing first-line therapy for metastatic colorectal cancer.

  Emily Noelle Kinsey, Nolan W. Wages, Katarzyna Tyc, Hamid Akbarali et al.
• E15508
  A generative model–assisted clinical decision support system for the postoperative management of colon cancer.

  Wenjing Gong, Chengzhi Gui, Ping Yang, Xinjia He et al.
• E15586
  Role of VISTA/TIM3 heterodimerization and macrophage metabolic reprogramming in microsatellite stable colorectal cancer.

  Fei Sun, Na Hong, Chunting Zeng, Jian Li et al.
• E15682
  Insurance-related disparities in emergency department presentation among hospitalized colorectal cancer patients: A national analysis.

  Mevlut Ozmen, Tanzeela Mariam Shuja, Lavanya Nagarajan, Ekow Pinkrah et al.
• 3650
  Cost-effectiveness analysis of aspirin and structured exercise as adjuvant therapy in localized colorectal cancer.

  Malek B. Hannouf, Kaiden Jobin, Olivia Yung, Navdeep Dehar et al.
• E15511
  Artificial intelligence–enabled analysis of prognostic PI3K pathway alterations in African American colorectal cancer patients treated with FOLFOX.

  Enrique Velazquez Villarreal, Brigette Waldrup, Francisco G. Carranza, Sophia Manjarrez et al.
• E15052
  Evaluation of serum folate receptor alpha levels in colon cancer: Association with diagnosis, clinical stage, and metastasis.

  Lutfullah Zahit Koc, Sevgi Gulsen Koc, Derya Kıvrak Salim, Nur Benil Yabaci et al.
• 3619
  Prediction of localized rectal cancer outcomes with ctDNA analysis using a novel ultrasensitive structural variant (SV)-based method.

  Cecilia Merk, Sofia Birkealv, Karen Howarth, Girish Putcha et al.
• E15513
  Large-scale EMR-based machine learning for early risk stratification of colorectal cancer.

  Igor V. Samoylenko, Andrey A. Novikov, Zakhra R. Magomedova, Valery V. Nazarova et al.
• 3552
  A phase II trial of fruquintinib combined with cadonilimab in refractory MSS/pMMR colorectal cancer with pulmonary metastases.

  Mengzhou Guo, Yiyi Yu, Xiaojing Xu, Jingyuan Wang et al.
• E15521
  TP53 loss in relation to mTORC1 activation and autophagy suppression shaping an immune-cold phenotype in microsatellite-stable colorectal cancer.

  Eunseuk Lee, Dana Al-Assi, Randy Rueda-Rivera, Anshu Sutihar
• E15615
  Building a patient-driven, integrated research infrastructure to accelerate therapeutic advances in colorectal cancer.

  Kimberley Lynn Newcomer, Travis Hyams, Tina Zeff, Marc Mason et al.
• E15590
  Genomic characterization of brain metastasis in colorectal cancer to reveal patterns of clonal evolution and selection of driver mutations.

  Heyuan Niu, Xiaoping Li, Anqi He, Kaiyu Li et al.
• E15733
  Role of oxidative stress and neutrophil reprogramming in mediating venous thrombosis in colorectal cancer.

  Shreyashree Sarkar, Meena Kumari Palani Kumar, Azaj Ahmed, Gokul Deoram Patil et al.
• E15601
  Cachexia index, allostatic load, and body composition phenotypes in racially and ethnically diverse patients with metastatic colorectal cancer.

  Brett Wagner, Yaroslava Bogdan, Victoria Gomez, Pokhraj Suthar et al.
• 1639
  Disparities in receipt of guideline-concordant adjuvant chemotherapy and survival outcomes among immigrant patients with colon cancer: Real-world evidence from Ontario.

  Bishal Gyawali, Jennifer Fleming, Meghan Bowman, Xuejiao Wei et al.
• 3562
  Single-cell atlas of peripheral blood immune landscape in pMMR/MSS rectal cancer treated with neoadjuvant chemoradiotherapy and PD-1 blockade.

  Leqi Zhou, Guanyu Yu, Tianshuai Zhang, Mengdi Chen et al.
• E23215
  Inpatient outcomes and resource utilization by complication clustering phenotypes among colorectal cancer hospitalizations in the United States.

  Michael Ghobrial, Faizan Sheraz, Arash Latifi, Elaine Patricia Tupas et al.
• E15599
  Comparative efficacy of PD-1 versus PD-L1 inhibitors in metastatic colorectal cancer: A real-world propensity score–matched study.

  Kushal Kriplani, Timothy J. Brown, Udhayvir Singh Grewal, Nicholas James Hornstein
• 3614
  Predicting neoadjuvant chemoradiotherapy response and postoperative recurrence in locally advanced rectal cancer using a preoperative large language model.

  Xiaoxi Chen, Kun Miao, Song Wang, Guofeng Sun et al.
• 11170
  Prevalence and fracture burden of osteoporosis among patients with colorectal cancer: A real-world analysis.

  Anushree Venkatesh Murthy, Logesh Durairaj, Adithya Nagendran, Madho Mal et al.
• E15653
  Extracellular and immune matrix signature of interstitial fluid as mediator of pathological characteristics of colorectal cancer.

  Guanyu Yu, Tianshuai Zhang, Leqi Zhou, Liming Sun et al.
• 3612
  Targeting the Warburg effect: Mitochondrial metabolic modulation with intermittent fasting during neoadjuvant chemoradiation in rectal cancer compared with standard neoadjuvant chemoradiation and total neoadjuvant therapy.

  Krithikaa Sekar, Lohith Gopala Reddy, Basavalinga Sadasivaiah Ajaikumar, Esther Sathiaraj et al.
• E15524
  First-line induction oxaliplatin-based chemotherapy followed by maintenance in isolated peritoneal metastatic colorectal cancer: Real-world outcomes from Vietnam.

  Huy Van Nguyen, Phuong Dinh, Tran Thang, Hoa Nguyen et al.
• E15556
  Association of GLP-1 receptor agonist use with overall survival in patients with colorectal cancer and type 2 diabetes: A multicenter real-world study.

  Baqir Jafry, Anahat Kaur, Jennifer Collins, Amir Kamran
• E15641
  Colorectal cancer detection with a multiomic liquid biopsy: Comparing and combining blood- and stool-based tests.

  James Munro Cameron, Peter Mitchell, Edward Parkin, Holly Butler et al.
• E15718
  Somatic and actionable genomic alterations in early-onset colorectal cancer versus late-onset disease: Experience from a western Florida tertiary referral center.

  Abigail Huetteman, Jessica Shostak, Aaron Bertolo, Satish Stephen Maharaj
• E15705
  Impact of tumor sidedness and social determinants of health on survival in early-onset colon cancer: A SEER 2004–2022 study.

  Tayyaba Saleem, Manzer Ali, Muhammad Ibrahim, Hareem Saleem et al.
• E15695
  Trends in early-onset colorectal cancer: A 20-year epidemiological study at a referral center in northeastern Mexico.

  Hector Alejandro Rodriguez-Calvillo, Omar A. Zayas, David Hernandez, Samantha Michelle Hinojosa Garcia
• E15638
  Neoadjuvant chemotherapy with NALIRIFOX for locally advanced colorectal cancer: A multicenter, single-arm, phase II trial.

  Zhenlin Hou, Gang Kong, Dagui Lin, Fulong Wang et al.
• E22530
  Evaluating CT-derived body composition and colorectal cancer risk: A group-based trajectory modeling morphomics study.

  Ryan Hood, Rajat Chandra, Catherine Blandon, Tracy E. Crane et al.
• E15628
  Unmasking the clinical impact of SGLT-2 inhibitors in stage IV colorectal cancer: A real-world multicenter analysis.

  Areeb Khan, Deevyashali Parekh, Ansy Patel, Eloho Olojakpoke et al.
• 3663
  Shifting dietary drivers of colorectal cancer mortality in the United States: A 33-year Global Burden of Disease analysis.

  Jennifer Kate Beckerman, Charbel Fadi Matar, Giorgi Sabakhtarishvili, Eunhee Choi
• 3662
  Impact of social determinants of health on women with early-onset colorectal cancer: A retrospective study.

  Elaine Ognjanovski, Niketh Chopra, Amaani Lewis, Muhammad Ismail et al.
• E15668
  Helicobacter pylori infection, systemic inflammation, and colorectal cancer: A prospectively enrolled case–control study.

  Saad Manzoor, Mounika Kotte, Abdul Ghani Iqbal, Zeeshan Hameed et al.
• 3554
  Tumor cell-intrinsic programs of metabolic adaptation and immune evasion in colorectal cancer liver metastases (CRCLMs).

  Xuanyi Li, Kerryan Ashley, Krishna Iyer, Thazin Nwe Aung et al.
• 3624
  Efficacy of probiotics combined with glutamine compound for acute radiation enteritis during neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A randomized controlled trial (NCT05406882).

  Qiaoli Wang, Shang Wang, Yuanling Tang, Feng Wen et al.
• TPS3687
  Node-sparing modified short-course radiotherapy combined with capecitabine and PD-1/CTLA-4 for MSS early, middle, and low rectal cancer (mRCAT-E): An open-label, single-arm, prospective multicenter clinical trial.

  Zhangfa Song, Bingjun Bai, Weifeng Lao, Min Chen
• E15624
  Impact of mRNA COVID-19 vaccination on survival in pembrolizumab-treated stage IV colon cancer: A multi-institutional propensity-matched analysis.

  Mohamed Jimale, Taha Hassan, Hisham Alsharif, Ali Raza Khan et al.
• E15699
  Incidence, prevalence, and temporal trends of colorectal cancer across age, sex, race, and ethnicity: A large real-world analysis.

  Logesh Durairaj, Anushree Venkatesh Murthy, Adithya Nagendran, Madho Mal et al.
• 10608
  Intensity of chemotherapy regimens for patients with Lynch syndrome and colorectal cancer.

  Christine M. Veenstra, Paul Abrahamse, Kevin C. Ward, Ann S. Hamilton et al.